|
1
|
Lozano R, Naghavi M, Foreman K, et al:
Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: a systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
Statistics 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Buyse M, Thirion P, Carlson RW,
Burzykowski T, Molenberghs G and Piedbois P: Relation between
tumour response to first-line chemotherapy and survival in advanced
colorectal cancer: a meta-analysis. Lancet. 356:373–378. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoff PM, Ansari R, Batist G, et al:
Comparison of oral capecitabine versus intravenous fluorouracil
plus leucovorin as first-line treatment in 605 patients with
metastatic colorectal cancer: results of a randomized phase III
study. J Clin Oncol. 19:2282–2292. 2001.
|
|
5
|
Porschen R, Arkenau HT, Kubicka S, et al:
Phase III study of capecitabine plus oxaliplatin compared with
fluorouracil and leucovorin plus oxaliplatin in metastatic
colorectal cancer: a final report of the AIO Colorectal Study
Group. J Clin Oncol. 25:4217–4223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fuchs CS, Marshall J, Mitchell E, et al:
Randomized, controlled trial of irinotecan plus infusional, bolus,
or oral fluoropyrimidines in first-line treatment of metastatic
colorectal cancer: results from the BICC-C Study. J Clin Oncol.
25:4779–4786. 2007. View Article : Google Scholar
|
|
7
|
de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
8
|
Saltz LB, Cox JV, Blanke C, et al:
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colucci G, Gebbia V, Paoletti G, et al:
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the
treatment of advanced colorectal cancer: a multicenter study of the
Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol.
23:4866–4875. 2005.PubMed/NCBI
|
|
10
|
Díaz-Rubio E, Tabernero J, Gómez-España A,
et al: Phase III study of capecitabine plus oxaliplatin compared
with continuous-infusion fluorouracil plus oxaliplatin as
first-line therapy in metastatic colorectal cancer: final report of
the Spanish Cooperative Group for the Treatment of Digestive Tumors
Trial. J Clin Oncol. 25:4224–4230. 2007.
|
|
11
|
Tol J, Koopman M, Cats A, et al:
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van Cutsem E, Peeters M, Siena S, et al:
Open-label phase III trial of panitumumab plus best supportive care
compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol.
25:1658–1664. 2007.PubMed/NCBI
|
|
13
|
Kubicka S, Greil R, André T, et al:
Bevacizumab plus chemotherapy continued beyond first progression in
patients with metastatic colorectal cancer previously treated with
bevacizumab plus chemotherapy: ML18147 study KRAS subgroup
findings. Ann Oncol. 24:2342–2349. 2013. View Article : Google Scholar
|
|
14
|
Van Cutsem E, Tabernero J, Lakomy R, et
al: Addition of aflibercept to fluorouracil, leucovorin, and
irinotecan improves survival in a phase III randomized trial in
patients with metastatic colorectal cancer previously treated with
an oxaliplatin-based regimen. J Clin Oncol. 30:3499–3506. 2012.
|
|
15
|
Saltz LB, Clarke S, Díaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hilgard P, Klenner T, Stekar J and Unger
C: Alkylphosphocholines: a new class of membrane-active anticancer
agents. Cancer Chemother Pharmacol. 32:90–95. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berkovic D: Cytotoxic ether-phospholipid
analogues. Gen Pharmacol. 31:511–517. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vink SR, van Blitterswijk WJ, Schellens
JHM and Verheij M: Rationale and clinical application of
alkylphospholipid analogues in combination with radiotherapy.
Cancer Treat Rev. 33:191–202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Blitterswijk WJ and Verheij M:
Anticancer mechanisms and clinical application of
alkylphospholipids. Biochim Biophys Acta. 1831:663–674.
2013.PubMed/NCBI
|
|
20
|
Yosifov DY, Todorov PT, Zaharieva MM,
Georgiev KD, Pilicheva BA, Konstantinov SM and Berger MR:
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a
potential antimyeloma drug devoid of myelotoxicity. Cancer
Chemother Pharmacol. 67:13–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Georgieva MC, Konstantinov SM,
Topashka-Ancheva M and Berger MR: Combination effects of
alkylphosphocholines and gemcitabine in malignant and normal
hematopoietic cells. Cancer Lett. 182:163–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bagley RG, Kurtzberg L, Rouleau C, Yao M
and Teicher BA: Erufosine, an alkylphosphocholine, with
differential toxicity to human cancer cells and bone marrow cells.
Cancer Chemother Pharmacol. 68:1537–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zaharieva MM, Konstantinov SM, Pilicheva
B, Karaivanova M and Berger MR: Erufosine - a membrane targeting
antineoplastic agent with signal transduction modulating effects.
Ann NY Acad Sci. 1095:182–192. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fiegl M, Lindner LH, Juergens M, Eibl H,
Hiddemann W and Braess J: Erufosine, a novel alkylphosphocholine,
in acute myeloid leukemia: single activity and combination with
other antileukemic drugs. Cancer Chemother Pharmacol. 62:321–329.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martelli AM, Papa V, Tazzari PL, et al:
Erucylphosphohomocholine, the first intravenously applicable
alkylphosphocholine, is cytotoxic to acute myelogenous leukemia
cells through JNK- and PP2A-dependent mechanisms. Leukemia.
24:687–698. 2010. View Article : Google Scholar
|
|
26
|
Königs SK, Pallascha CP, Lindnerb LH, et
al: Erufosine, a novel alkylphosphocholine, induces apoptosis in
CLL through a caspase-dependent pathway. Leuk Res. 34:1064–1069.
2010.PubMed/NCBI
|
|
27
|
Yosifov DY, Reufsteck C, Konstantinov SM
and Berger MR: Interleukin-6, osteopontin and Raf/MEK/ERK signaling
modulate the sensitivity of human myeloma cells to
alkylphosphocholines. Leuk Res. 36:764–772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Konstantinov SM and Berger MR: Human
urinary bladder carcinoma cell lines respond to treatment with
alkylphosphocholines. Cancer Lett. 144:153–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dineva IK, Zaharieva MM, Konstantinov SM,
Eibl H and Berger MR: Erufosine suppresses breast cancer in vitro
and in vivo for its activity on PI3K, c-Raf and Akt proteins. J
Cancer Res Clin Oncol. 138:1909–1917. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kapoor V, Zaharieva MM, Das SN and Berger
MR: Erufosine simultaneously induces apoptosis and autophagy by
modulating the Akt-mTOR signaling pathway in oral squamous cell
carcinoma. Cancer Lett. 319:39–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lemeshko VV and Kugler W: Synergistic
inhibition of mitochondrial respiration by anticancer agent
erucylphosphohomocholine and cyclosporin A. J Biol Chem.
282:37303–37307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rübel A, Handrick R, Lindner LH, et al:
The membrane targeted apoptosis modulators erucylphosphocholine and
erucylphosphohomocholine increase the radiation response of human
glioblastoma cell lines in vitro. Radiat Oncol. 1:62006.
|
|
33
|
Veenman L, Alten J, Linnemannstöns K, et
al: Potential involvement of F0F1-ATP(synth)ase and reactive oxygen
species in apoptosis induction by the antineoplastic agent
erucylphosphohomocholine in glioblastoma cell lines: a mechanism
for induction of apoptosis via the 18 kDa mitochondrial
translocator protein. Apoptosis. 15:753–768. 2010.
|
|
34
|
Rudner J, Ruiner CE, Handrick R, Eibl HJ,
Belka C and Jendrossek V: The Akt-inhibitor erufosine induces
apoptotic cell death in prostate cancer cells and increases the
short term effects of ionizing radiation. Radiat Oncol. 5:1082010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berger MR, Tsoneva I, Konstantinov SM and
Eibl H: Induction of apoptosis by
erucylphospho-N,N,N-trimethylammonium is associated with
changes in signal molecule expression and location. Ann NY Acad
Sci. 1010:307–310. 2003.PubMed/NCBI
|
|
36
|
Sobottka SB and Berger MR: Assessment of
antineoplastic agents by MTT assay: partial underestimation of
antiproliferative properties. Cancer Chemother Pharmacol.
30:385–393. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sobottka SB, Berger MR and Eibl H:
Structure-activity relationships of four anti-cancer
alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer.
53:418–425. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: a convenient and inexpensive method or analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rothbarth J, Koevoets C, Tollenaar RA,
Tilby MJ, van de Velde CJ, Mulder GJ and Kuppen PJ:
Immunohistochemical detection of melphalan-DNA adducts in colon
cancer cells in vitro and human colorectal liver tumours in
vivo. Biochem Pharmacol. 67:1771–1778. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Haynes RH, Eckardt F and Kunz BA: The DNA
damage-repair hypothesis in radiation biology: comparison with
classical hit theory. Br J Cancer. 49:81–90. 1984.PubMed/NCBI
|
|
42
|
Orr JS: Concepts, problems and the role of
modifying agents in the relationship between recovery of cells’
survival ability and mechanisms of repair of radiation lesions. Br
J Cancer (Suppl). 49:1–6. 1984.PubMed/NCBI
|
|
43
|
Hall EJ and Brenner DJ: Radiobiology of
low- and high-dose-rate brachytherapy. Technical Basis of Radiation
Therapy. 4th edition. Levitt SH, Purdy JA, Perez CA and Vijayakumar
S: Springer Verlag; Berlin: pp. 291–307. 2008
|
|
44
|
Miura K, Fujibuchi W, Ishida K, et al:
Inhibitor of apoptosis protein family as diagnostic markers and
therapeutic targets of colorectal cancer. Surg Today. 41:175–182.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Georges RB, Adwan H, Hamdi H, Hielscher T,
Linnemann U and Berger MR: The insulin-like growth factor binding
proteins 3 and 7 are associated with colorectal cancer and liver
metastasis. Cancer Biol Ther. 12:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kawamura M, Toiyama Y, Tanaka K, et al:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kabra N, Li Z, Chen L, et al: SirT1 is an
inhibitor of proliferation and tumor formation in colon cancer. J
Biol Chem. 284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yosifov DY, Dineva IK, Zaharieva MM,
Konstantinov SM and Berger MR: The expression level of the tumor
suppressor retinoblastoma protein (Rb) ınfluences the antileukemic
efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3).
Cancer Biol Ther. 6:930–935. 2007.
|
|
49
|
DeGregori J: The Rb network. J Cell Sci.
117:3411–3413. 2004. View Article : Google Scholar
|
|
50
|
Kugler W, Buchholz F, Köhler F, Eibl H,
Lakomek M and Erdlenbruch B: Downregulation of Apaf-1 and caspase-3
by RNA interference in human glioma cells: consequences for
erucylphosphocholine-induced apoptosis. Apoptosis. 10:1163–1174.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang SY, Bolvin C, Sales KM, Fuller B,
Seifalian AM and Winslet MC: IGF-I activates caspases 3/7, 8 and 9
but does not induce cell death in colorectal cancer cells. BMC
Cancer. 9:1582009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nhan TQ, Liles WC and Schwartz SM:
Physiological functions of caspases beyond cell death. Am J Pathol.
169:729–737. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bröker LE, Kruyt FAE and Giaccone G: Cell
death independent of caspases: a review. Clin Cancer Res.
11:3155–3162. 2005.
|
|
54
|
Naumann U, Wischhusen J, Weit S, Rieger J,
Wolburg H, Massing U and Weller M: Alkylphosphocholine-induced
glioma cell death is BCL-XL-sensitive, caspase-independent and
characterized by massive cytoplasmic vacuole formation. Cell Death
Differ. 11:1326–1341. 2004. View Article : Google Scholar
|
|
55
|
Eibl KH, Kook D, Priglinger S, Haritoglou
C, Yu A, Kampik A and Welge-Lussen U: Inhibition of human retinal
pigment epithelial cell attachment, spreading, and migration by
alkylphosphocholines. Invest Ophthalmol Vis Sci. 47:364–370. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hendriks T, Martens MF, Huyben CM and
Wobbes T: Inhibition of basal and TGFJ-induced fibroblast collagen
synthesis by antineoplastic agents. Implications for wound healing.
Br J Cancer. 67:545–550. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Louneva N, Saitta B, Herrick DJ and
Jimenez SA: Transcriptional inhibition of type I collagen gene
expression in scleroderma fibroblasts by the antineoplastic drug
ecteinascidin 743. J Biol Chem. 278:40400–40407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Seet LF, Su R, Toh LZ and Wong TT: In
vitro analyses of the anti-fibrotic effect of SPARC silencing in
human Tenon’s fibroblasts: comparisons with mitomycin C. J Cell Mol
Med. 16:1245–1259. 2012.PubMed/NCBI
|
|
59
|
Auman JT and McLeod HL: Colorectal cancer
cell lines lack the molecular heterogeneity of clinical colorectal
tumors. Clin Colorectal Cancer. 9:40–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
